HomepageGRAL • NASDAQ
add
Grail Inc
Vorige slotkoers
$ 96,70
Dag-range
$ 93,00 - $ 106,25
Jaar-range
$ 17,50 - $ 115,76
Beurswaarde
4,09 mld. USD
Gem. volume
761,33K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 36,19 mln. | 26,32% |
Bedrijfskosten | 145,03 mln. | -25,53% |
Netto inkomsten | -88,98 mln. | 29,21% |
Netto winstmarge | -245,83 | 43,96% |
Winst per aandeel | -2,46 | 29,77% |
EBITDA | -86,31 mln. | 40,18% |
Effectief belastingtarief | 25,05% | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 540,13 mln. | -36,72% |
Totale activa | 2,60 mld. | -16,58% |
Totale passiva | 361,07 mln. | -31,91% |
Totaal aandelenvermogen | 2,24 mld. | — |
Uitstaande aandelen | 38,98 mln. | — |
Koers-boekwaardeverhouding | 1,56 | — |
Rendement op activa | -11,81% | — |
Rendement op kapitaal | -13,40% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -88,98 mln. | 29,21% |
Operationele kasstroom | -63,24 mln. | 39,53% |
Kasstroom uit beleggingen | 66,67 mln. | 6.966,43% |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | 3,09 mln. | 102,93% |
Vrije kasstroom | -19,27 mln. | 60,50% |
Over
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 Galleri launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
Opgericht
2015
Hoofdvestiging
Website
Werknemers
1.000
